{"id":"spd503-3-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism reduces airway inflammation and mucus production, making it suitable for respiratory inflammatory conditions.","oneSentence":"SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:49.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT01500694","phase":"PHASE3","title":"Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-20","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":215},{"nctId":"NCT00901576","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-05-18","conditions":"Healthy","enrollment":38},{"nctId":"NCT00152009","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2003-01-29","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":345},{"nctId":"NCT00150618","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2004-03-30","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":324},{"nctId":"NCT03662763","phase":"PHASE3","title":"Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-09","conditions":"Attention Deficit Disorder","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPD503 (3 mg)","genericName":"SPD503 (3 mg)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}